Bert Oosting > Hogan Lovells International LLP > Amsterdam, Netherlands > Lawyer Profile

Hogan Lovells International LLP
ATRIUM - NORTH TOWER
STRAWBSYLAAN 4129
1077 ZX AMSTERDAM PO BOX 545
Netherlands

Work Department

Intellectual Property

Position

Partner

Career

widely recognized as one of the leading, go-to practitioners for international patent and complex technology disputes. Bert’s practice encompasses all areas of intellectual property and life sciences. He regularly lectures on these areas of law and is a prolific writer and speaker on this topic.

Languages

English, German, French, Italian, Dutch

Memberships

nternational Association of Defense Counsel; International Association for the Protection of Intellectual Property; Licensing Executives Society

Education

University of Utrecht, 1989

University of Utrecht, 1986

Lawyer Rankings

Netherlands > Industry focus: healthcare and life sciences

(Leading individuals)

Bert OostingHogan Lovells International LLP

Hogan Lovells International LLP‘s life sciences and healthcare regulatory practice works in conjunction with its patent practice, especially in connection with multi-jurisdictional patent litigation. Hein Van den Bos and Bert Oosting head a large group of specialists covering areas including regulatory compliance on drugs, medical devices, veterinary, products and new technologies, as well as clinical trials. Senior associate Ruth Franken is noted for her extensive experience in EU and Dutch regulatory, pricing, and reimbursement matters. The practice advises major European and international clients including Merck Sharp & Dohme, Intervet, and Lilly.

Netherlands > Intellectual property: Patents

Ruud van der Velden heads the team at Hogan Lovells International LLP and together with Bert Oosting and Klaas Bisschop attracts complex patent infringement work in the pharma, chemicals and electronics arenas together with regulatory matters. The team acted for Merck Sharp & Dohme in a landmark case against Teva that went to the Supreme Court and concerned a second medical use patent protecting a combination therapy for the treatment of hepatitis C.